Prognostic Model for Stage III Colon Cancer Patients Based on Histological Grade, CEA and NLR

With approximate one million new cases every year (Barton, 2012), colon cancer is one of the most severe health burdens all over the world. For stage III colon cancer (T1~4N1~2), standard treatment had been established as radical surgery followed by adjuvant chemotherapy (Moertel et al., 1990; Kuebler et al., 2007; Cassidy et al., 2008) since 1990. However, the treatment outcomes are not as desiredabout 60% stage III patients eventually die from tumor relapse (O’Connell et al., 2004; Giraldez et al., 2013) within five years. Far from a homogeneous patients group, patients with stage III colon cancer in fact harbor subgroups with notably diverse clinical outcomessince the five year survival rate ranges from 44% to 83% (Wong et al.,